Viracta Therapeutics' NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. (Nasdaq: VIRX) has announced that its pivotal NAVAL-1 clinical trial has achieved the efficacy threshold for expansion in relapsed or refractory EBV-positive peripheral T-cell lymphoma (R/R EBV+ PTCL). This milestone allows the trial to move into Stage 2, indicating a strong signal of efficacy in treating this type of cancer. The NAVAL-1 trial is a global, multicenter ..